| Two‐stage log‐rank fixed‐effect meta‐analysis | Results based on IPD analysis | Including additional literature based data |
| ESA versus control | HR (95% CI) | HR (95% CI) |
| Overall survival, all cancer patients | 1.06 (1.00‐1.12) | 1.06 (1.00‐1.11) |
| Overall survival, chemotherapy trials | 1.04 (0.97‐1.11) | 1.04 (0.97‐1.11) |